Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Neutrolis, Remora Therapeutics

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb's 2017 Golden Tickets for LabCentral. As a platinum sponsor of LabCentral, Bristol-Myers Squibb can select up to two innovative life-sciences and biotech startup companies per year of active sponsorship for "Golden Tickets," which underwrite the cost of one lab bench for one year in LabCentral's Kendall Square facility.

"We are delighted to award Golden Tickets to Neutrolis and Remora Therapeutics, two emerging, innovative companies with significant scientific potential," said Carl Decicco, Ph.D., Head of Discovery at Bristol-Myers Squibb. "The winners align with our commitment to enabling scientific innovation in our research areas of focus. We look forward to seeing these promising companies advance their research programs at LabCentral. Our sponsorship of LabCentral has facilitated important collaborations between Bristol-Myers Squibb researchers and the Cambridge community, as we prepare for our research site opening in Cambridge next year."

Neutrolis is a preclinical drug discovery company focused on researching new potential treatment options for inflammatory diseases where uncontrolled neutrophilic inflammation may be implicated, such as lupus and sepsis. Neutrophils are the predominant white blood cells present during acute inflammation. When patients are unable to regulate this inflammatory process, it can lead to worsening of disease. Using its proprietary genetic technology platform, Neutrolis is developing therapeutics with the goal of neutralizing excessive neutrophilic inflammation, as well as companion diagnostics to identify patients who are most likely to benefit from such therapeutics.

Remora Therapeutics is a preclinical-stage biotechnology company focused on developing novel platelet-based cell therapies. Platelets are best known for their role in blood clotting, but they are also involved in the pathogenesis of many major human diseases, including cancer and conditions of autoimmunity. Remora’s proprietary technology is designed to engineer platelets to fight disease, and improve the quality of life for patients living with debilitating illness.

"Bristol-Myers Squibb’s first two Golden Ticket winners, PanTher and Suono Bio, have each met important research milestones and have been terrific contributors to the LabCentral community," commented LabCentral Cofounder and President Johannes Fruehauf, M.D., Ph.D. "We are pleased to welcome Neutrolis and Remora Therapeutics - impressive startups - and we expect that they will likewise thrive here."

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About LabCentral

LabCentral is a first-of-its-kind shared laboratory workspace in the heart of the Kendall Square, Cambridge, biotech innovation hub. Designed as a launchpad for high-potential life-sciences and biotech startups, it offers everything startups need to begin laboratory operations on day one and move their science forward faster and more cost-efficiently. This includes: fully permitted laboratory and office space, first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series - as well as the other critical services and support. A private, nonprofit institution, LabCentral's first site opened in 2013, thanks to a capital grant from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Founding sponsors include Triumvirate Environmental and Johnson & Johnson Innovation. To accommodate demand for its growing startups, LabCentral, with support from Pfizer, Inc., plans to open LabCentral 610 in December 2017. In 2018, LabCentral will have capacity to serve a total of ~450 scientists and entrepreneurs in about 70 companies across its two-building campus.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Novartis' Ultibro® Breezhaler® significantly impro…

Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) pati...

New Novartis Entresto® real world evidence data sh…

Novartis has announced new results from a real-world database study of patients in Germany prescribed Entresto® (sacubitril/valsartan) for heart failure with reduced ejec...

FDA approves pill with sensor that digitally track…

The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) ...

Scientists find natural mimetics of anti-cancer …

Researchers from the Biogerontology Research Foundation, Insilico Medicine, Life Extension and other institutions announce the publication of a landmark study in the jour...

Novartis, ASCP and ACS join forces to fight cancer…

Novartis, the American Society for Clinical Pathology (ASCP) and the American Cancer Society (ACS) will work together to devise a common approach to improve access to ca...

World's smallest tape recorder is built from micro…

Through a few clever molecular hacks, researchers at Columbia University Medical Center have converted a natural bacterial immune system into a microscopic data recorder...

Using social media big data to combat prescription…

Researchers at Dartmouth, Stanford University, and IBM Research, conducted a critical review of existing literature to determine whether social media big data can be used...

Discovery of a promising medication for amyotrophi…

Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medi...

Sclerosis medicine can fight multi-resistant bacte…

Encountering bacteria with innocent names such as Pseudomonas aeruginosa and Enterobacteriaceae can lead to hospitalisation and - in a worst-case scenario - can also be l...

Mushrooms are full of antioxidants that may have a…

Mushrooms may contain unusually high amounts of two antioxidants that some scientists suggest could help fight aging and bolster health, according to a team of Penn State...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]